

UC San Diego

UC San Diego Previously Published Works

Title

Mutations in Spliceosomal Genes PPIL1 and PRP17 Cause Neurodegenerative Pontocerebellar Hypoplasia with Microcephaly

Permalink

<https://escholarship.org/uc/item/6w53352f>

Journal

Neuron, 109(2)

ISSN

0896-6273

Authors

Chai, Guoliang
Webb, Alice
Li, Chen
[et al.](#)

Publication Date

2021

DOI

10.1016/j.neuron.2020.10.035

Peer reviewed



HHS Public Access

Author manuscript

Neuron. Author manuscript; available in PMC 2022 January 29.

Published in final edited form as:

Neuron. 2021 January 20; 109(2): 241–256.e9. doi:10.1016/j.neuron.2020.10.035.

Mutations in spliceosomal genes *PPIL1* and *PRP17* cause neurodegenerative pontocerebellar hypoplasia with microcephaly

Guoliang Chai^{1,2,15}, Alice Webb^{3,15}, Chen Li^{1,2}, Danny Antaki^{1,2}, Sangmoon Lee^{1,2}, Martin W. Breuss^{1,2}, Nhi Lang^{1,2}, Valentina Stanley^{1,2}, Paula Anzenberg^{1,2}, Xiaoxu Yang^{1,2}, Trevor Marshall^{1,2}, Patrick Gaffney⁴, Klaas J. Wierenga⁵, Brian Hon-Yin Chung⁶, Mandy Ho-Yin Tsang⁶, Lynn S. Pais⁷, Alysia Kern Lovgren⁷, Grace E. VanNoy⁷, Heidi L. Rehm⁷, Ghayda Mirzaa⁸, Eyby Leon⁹, Jullianne Diaz⁹, Alexander Neumann¹⁰, Arnout P. Kalverda¹¹, Iain W. Manfield¹¹, David A. Parry³, Clare V. Logan³, Colin A. Johnson³, David T. Bonthron³, Elizabeth MA Valleley³, Mahmoud Y. Issa¹², Sherif F. AbdelGhafar¹³, Mohamed S. Abdel-Hamid¹³, Patricia Jennings¹⁴, Maha S. Zaki¹², Eamonn Sheridan^{3,*}, Joseph G. Gleeson^{1,2,16,*}

¹Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA

²Rady Children's Institute for Genomic Medicine, San Diego, CA 92130, USA

³Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, LS9 7TF, UK

⁴Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA

⁵Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL 32224, USA

⁶Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, U Hong Kong, SAR, China

⁷Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

⁸Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA

⁹Department of Genetics and Metabolism, Children's National Hospital, Washington DC 20010, USA

*Correspondence: e.sheridan@leeds.ac.uk (E.S.), jogleeson@ucsd.edu (J.G.G.).

AUTHOR CONTRIBUTIONS

GC, AW, ES, and JGG conceived the project and wrote the manuscript with input from all coauthors. CL, DA, SL, XY provided computational support, VS, PA, MWB supported mouse work, PG, KJW, BH-Y C, M H-Y T, LSP, AKL, GEVN, HLR, RM, EL, JD, AN, DP, EMAV, DTB, CJ, MSA, SA, MYI, and MZ recruited patients, LK, AK, IM PJ performed NMR.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹⁰Freie Universität Berlin, Institute of Chemistry and Biochemistry, Laboratory of RNA Biochemistry, Berlin, 14195, Germany

¹¹Astbury Centre for Structural Molecular Biology and Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK

¹²Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo 12311, Egypt

¹³Medical Molecular Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo 12311, Egypt

¹⁴Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA

¹⁵These authors contributed equally

¹⁶Lead Contact

SUMMARY

Autosomal-recessive cerebellar hypoplasia and ataxia comprise a group of heterogeneous brain disorders, caused by disruption of several fundamental cellular processes. Here, we identified 10 families showing a neurodegenerative condition involving pontocerebellar hypoplasia with microcephaly (PCHM). Patients harbored biallelic, mutations in genes encoding the spliceosome components Peptidyl-Prolyl Isomerase Like-1 (PPIL1) or Pre-RNA Processing-17 (PRP17). Mouse knockouts of either gene were lethal in early embryogenesis, whereas *PPIL1* patient mutation knockin mice showed neuron-specific apoptosis. Loss of either protein impacted splicing integrity, predominantly affecting short and high GC-content introns and genes involved in brain disorders. PPIL1 and PRP17 form an active isomerase-substrate interaction, however, we found isomerase activity is not critical for function. Thus, we establish disrupted splicing integrity and ‘major spliceosome-opathies’ as a new mechanism underlying PCHM and neurodegeneration, and uncover a non-enzymatic function of a spliceosomal proline isomerase.

eTOC Blurp

Chai et al. discover that loss of splicing factors PPIL1 and PRP17 lead to a neurodegenerative brain disease, and even though they are an enzyme-substrate pair, they function instead to scaffold the spliceosome.

Keywords

Pontocerebellar hypoplasia; microcephaly; neurodegeneration; brain development; spliceosome; cyclophilin; proline isomerase; alternative splicing; PCHM; PPIL1; PRP17; NMR; recessive disease

INTRODUCTION

Pontocerebellar hypoplasia (PCH) refers to a group of severe pediatric-onset neurodegenerative disorders affecting cellular survival in the brainstem and cerebellum,

resulting in impaired neurological function and early death (Cassandrini et al., 2010). Humans with PCH show near-normal early embryologic development, followed by midgestational slowing or cessation and later regression in select neuroanatomical regions (Joseph et al., 2014). Most genes implicated in PCH are involved in tRNA splicing or GTP availability, suggesting a potential effect on protein translation (Breuss et al., 2016; Budde et al., 2008; Karaca et al., 2014; Schaffer et al., 2014). While postnatal progressive microcephaly can be part of the clinical spectrum, children are mostly born with normal or only mildly reduced head circumference (van Dijk et al., 2018).

Pre-mRNA splicing, mediated by the spliceosome complex, is essential for gene expression and regulation in higher organisms (Shi, 2017; Will and Luhrmann, 2011). Increased splicing complexity results in dramatically enlarged diversity in both the transcriptome and proteome: for instance, 95% of multi-exon human genes undergo alternative splicing (AS). Not surprisingly, AS is especially prevalent in the brain, corresponding to its complex composition of cell types and functions (Raj and Blencowe, 2015; Zhang et al., 2016). Remarkably, while aberrant splicing of individual genes due to defective cis- or trans-regulation has been widely reported in human brain diseases, global splicing defects by mutations in core major spliceosome complex (MSC) components have rarely been associated (Chabot and Shkreta, 2016; Scotti and Swanson, 2016).

Incorporated within the MSC are eight cyclophilin peptidyl-prolyl isomerases (PPIase), enzymes initially found as targets of immunosuppressants, but later found to promote conformational changes of substrates by catalyzing cis-trans isomerization of Xaa-Proline peptide bond (Agafonov et al., 2011; Bessonov et al., 2010; Davis et al., 2010; Evans et al., 1987; Rajiv and Davis, 2018; Teigelkamp et al., 1998; Zhou et al., 2002). Functions and substrates of most PPIases remain unknown. Here, we report that biallelic, hypomorphic mutations in two spliceosomal genes *PPIL1* and *PRP17*, encoding an active PPIase-substrate pair, disrupt RNA splicing integrity and cause converging neurodegenerative phenotypes in human and mouse. While both proteins are required for splicing integrity and neuronal survival, surprisingly, mutations preventing PRP17 isomerization catalyzed by PPIL1 are tolerated, thus revealing a predominant non-enzymatic function of a spliceosomal PPIase.

RESULTS

Identification of biallelic mutations in *PPIL1* in PCHM families

From our cohort of 7,288 patients with recessive congenital neurological disorders, we identified rare damaging homozygous missense variants in *PPIL1* among 8 index cases from 5 families (Figures 1A–1C). All patients showed both features of PCH as well as congenital microcephaly (–3SD to –6SD HC); the latter phenotype progressed postnatally for all. Patients did not show features of known syndromic PCH subtypes (Akizu et al., 2013; Namavar et al., 2011) (Table 1 and Table S1). All subjects were enrolled with IRB-approved protocols at referral institutions and provided signed consent. Through Genematcher (Sobreira et al., 2015), we identified 4 additional families with 8 affected patients in which *PPIL1* mutations were independently identified as the likely cause (Table S1 and S2). As all individuals exhibited PCH with microcephaly, we defined this presentation as a unique clinical entity, which we termed PCHM (PCH+Microcephaly).

Further common phenotypes included hypotonia, difficulty swallowing, failure to control the airway, seizures, and delayed motor and language development. Brain MRI showed cortical changes in most affected (Figure 1B and Table S1), notably simplified gyri pattern, which was rarely reported for other subtypes of PCH.

The mutations in each family segregated with the phenotype according to recessive inheritance. Families 1–5 showed homozygous missense variants, and Family 6 showed two separate homozygous variants predicting a 6 aa duplication and a p.G109C substitution. Family 7–9 showed compound heterozygous variants: Families 5 and 7 and Family 8 and 9 shared an identical variant. All substituted residues were highly conserved (Figure S1A), predicted ‘damaging’ by MutationTaster (Schwarz et al., 2014), and clustered within PPIL1’s cyclophilin PPIase domain, suggesting deleterious functions (Figure 1C).

Patient mutations affect PPIL1 function

PPIL1 joins the MSC together with its interacting protein SKIP, two of the NineTeen complex-related proteins, during B complex formation, and remains until splicing is complete (Rajiv and Davis, 2018; Wang et al., 2010). We mapped human mutations onto the ordered globular PPIL1 structure (Xu et al., 2006), and found all the affected residues except p.R131 were located on the enzymatic face (Figure 1D). To test the impacts of patient variants, we expressed FLAG-tagged mutant protein in HEK293T cells and found most variants led to unstable proteins (Figures S1B and S1C). Specifically, p.Y78C, p.A99T, p.[A101_D106dup;G109C], p.F82S and to a lesser degree p.T127A were barely detectable. Likewise, reduced endogenous p.A99T PPIL1 protein was also observed in patient fibroblasts, which showed a slightly higher RNA possibly due to compensatory upregulation (Figure S1D–S1F).

Two variants, including p.T107A and p.R131Q, did not show altered protein levels in HEK293T cells. However, we found that both purified mutant proteins showed reduced thermal stability and increased aggregation propensity (Figures S1G–S1I). PPIL1 associates with SKIP prior to its incorporation into the spliceosome (Wang et al., 2010; Xu et al., 2006). The SKIP binding interface is located on the non-enzyme face (Wang et al., 2010; Xu et al., 2006), and previous studies suggested that PPIL1 p.R131 was involved in the binding to SKIP (Wang et al., 2010; Xu et al., 2006). As expected, we found that purified p.R131Q PPIL1 failed to associate with SKIP in both surface plasmon resonance and immunoprecipitation assays (Figures S1J and S1K). PPIL1 p.T107A, although localized to the enzymatic face, showed reduced SKIP interaction (Figure S1J). Thus, all assessed PPIL1 patient mutations either affect protein stability or interaction with SKIP.

Defective brain development and neuron-specific apoptosis in knockin mice

To reveal functions of PPIL1 in brain development, we studied expression during development. RNA *in situ* hybridization showed ubiquitous *Ppil1* expression in the developing cortex (Figures 2A and 2B). Due to a lack of specific PPIL1 antibodies, we generated a CRISPR knockin mouse introducing an N-terminal HA epitope in *Ppil1*, which confirmed ubiquitous protein expression (Figures 2C, 2D, and S2A–S2D). We next generated a *Ppil1* frameshift mouse line (*fs*, c.302delC, p.N102Tfs*13), but found no viable

homozygous embryos any time after embryonic day (E) 12.5 (0 in 41 embryos, $p < 0.00001$, Binomial test), while *Ppil1^{fs/+}* pups were indistinguishable from wild-type (WT) littermates. However, at E9.5 we recovered several partially resorbed embryos, all of which were genotyped as *Ppil1^{fs/fs}* (13 mutants in 46 embryos, with the expected 25%, Figures 2E and S2E). We conclude that *Ppil1* is essential for embryogenesis.

We next generated a patient p.A99T knockin (KI) mouse line, chosen because it was the first allele we identified. *Ppil1^{A99T/A99T}* mice were born at the expected Mendelian ratios (22 *Ppil1^{A99T/A99T}*, 42 *Ppil1^{A99T/+}*, and 23 WT), but died within 24h. Newborns showed smaller head size, severely reduced cerebral and cerebellar size, reduced cortical surface area and thickness (Figures 2F–2M atching human PCH While the cortex showed normal lamination, neuronal numbers were severely reduced, with CUX1⁺ upper layer neurons decreased by ~25% and CTIP2⁺ deep layer neurons by ~60% (Figures 2N and 2O). Like patient fibroblast, PPIL1 protein was also severely reduced by ~80% in *Ppil1^{A99T/A99T}* bryo lysates (Figures S2F and S2G). Additionally, compound heterozygous *Ppil1^{A99T/fs}* mutant embryos showed much more severe phenotypes across the body at E18.5 (Figure S2H), suggesting that *PPIL1* p.A99T is a hypomorphic mutation.

Based on the severe reduction in cortical thickness and neuronal numbers, we hypothesized that this could be caused by cell death during embryonic development. We examined apoptosis by assessing cleaved caspase 3 (CC3) and p53 expression in the embryonic brains. Indeed, the apoptosis showed a striking accumulation in TUJ1⁺ neurons within deep layers of the lateral cortical margin in the mutant brains starting at E12.5 and dramatic at E14.5 (Figures 3A–3F), with some apoptotic cells are GAD65/ interneurons (Figures S2I and S2J). The apoptosis in the rest of the cortex appeared at E14.5 and turned to be massive at E16.5 (Figures 3A–3N). Apoptotic cells predominantly localized in the cortical plate and did not overlap with SOX2⁺ neural stem cells (NSCs) and TBR2⁺ intermediate neural progenitors (INPs) (Figures 3G–3N and S2K–S2M). ~70% of p53 positive cells were positive for CTIP2 and ~30% for CUX1, consistent with a more severe reduction of deep layer neurons. CC3 upregulation was also observed in the cerebellum and pons at E18.5 (Figure S2N and S2O). Consistent with the predominant impact of the brain in the patients and KI mutant mice, no significant upregulation of apoptosis was observed in other major organs (Figures S2P and S2Q).

Recent studies proposed MSC defects result in genome instability, due partially to accumulated R-loops, transient RNA:DNA hybrid structures that displace the non-templated strand and generate susceptibility to DNA damage (Jangi et al., 2017; Paulsen et al., 2009), evidenced by γ -H2AX and p53 accumulation (Denis et al., 2005; Sorrells et al., 2018). Like p53, we indeed observed a dramatic upregulation of γ -H2AX in the mutant brains (Figures 3M, 3N, and S2L), suggesting similar mechanisms.

In contrast to other genetic models of microcephaly (Gruber et al., 2011; Insolera et al., 2014; Silver et al., 2010), no premature neurogenesis was observed at E12.5 (Figures S3A and S3B), and apoptosis initiation through p53 was predominantly localized to postmitotic neurons but not neural progenitors; consequently, the numbers of both neural stem cells (NSCs) and intermediate progenitors (INPs) only showed a slight reduction (Figures 3O–

3X). The cell cycle of the mutant progenitors seems not to undergo dramatic alterations, as we only observed a slightly increased percent of INPs at the G2/M phase (Figures S3C–S3F). Together, our results suggest genotoxic stress, neuronal apoptosis, and perturbations of progenitors lead to brain volume loss in *Ppil1* KI mutants.

PPIL1 is required for alternative splicing integrity

Despite its discovery in the spliceosome many years ago (Rappsilber et al., 2002), the function of PPIL1 in RNA splicing remains mostly unknown. Since *Ppil1^{fs/fs}* embryos survived until E9.5, we suspected that some cells might tolerate a complete loss of *PPIL1*. Thus, we generated *PPIL1* knockout (KO) human HAP1 cells (Figure S4A), which were viable and subjected to RNA-seq. Five different forms of alternative splicing (AS), including skipped exons (SE), mutually exclusive exons (MXE), alternative 5' and 3' splice sites selection (A5SS and A3SS), and retained introns (RI), were evaluated using rMATS software (Shen et al., 2014). We benchmarked rMATS by comparing significant differential splicing events (SDSE) were identified from 231,850 total AS vents (Table S3). In contrast, 8,602 (i.e. 3.4%) SDSEs were identified comparing 3 KO vs. 3 controls, with the number of SDSEs scaling with number replicates in each group (Figures S4B and S4C). We repeated the computational analysis using LeafCutter (Li et al., 2018), which identified 951 SDSEs between 3 KO vs. 3 controls, compared with 8 and 0 SDSEs for 3 controls vs. 3 controls vs. 3 KO vs. 3 KO (Table S3), respectively. All these revealed a dramatic disruption of global AS integrity upon loss of PPIL1.

We also confirmed altered AS by assessing ‘sashimi-plot pile-ups’ of RNAseq and performing RT-PCR validation on selected RI and SE events (Figures S4D–S4H). Loss of PPIL1 predominantly impacted the splicing of short and high GC-content introns, without significant bias towards splice site strength (Figures S4I–S4M). The most severe changes were present in introns 75 bp in length and with > 70% GC content (Figures S4N and S4O), where 12.6% of such introns were retained at higher levels in KO cells, compared with only 0.66% higher in controls.

Finally, we compared the list of SDSE genes in KO with OMIM disease categories based upon organ system involved and found overrepresentation for neurodevelopmental disease ($p = 3.45 \times 10^{-20}$, Bonferroni corrected Chi-squared test, Figure S4P), but not for cancer, cardiac or immune disease ($p > 0.05$). We also found that SDSE genes were significantly enriched in genes known to undergo AS in the brain ($p = 1.12 \times 10^{-287}$, Figure S3L). All these findings are consistent with its predominant impact on the brain.

Disrupted alternative splicing integrity in *Ppil1^{A99T/A99T}* brains

To test the impact of its loss on AS integrity in the brain tissue, we performed RNAseq on 3 WT and 3 *Ppil1^{A99T/A99T}* KI E14.5 brains before the accumulation of apoptotic cells. Using rMATS, we detected 3,797 SDSE among 236,870 total AS events (i.e. 1.6%, Figures 4A and S5A–S5C). Splicing alterations were also confirmed with Leafcutter, which identified 115 SDSE of 16,528 total AS events (i.e. 0.7%). A randomly selected group of significant RI and SE events were verified in semi-quantitative RT-PCR (Figures S5D and S5E). Two ‘minigene’ constructs transfected into MEFs for the SDSE introns of *Atg4d* and *Evi5l*

confirmed that the splicing defects were not secondary to non-specific effects (Figures 4B and S5F). Similar to HAP1 cells, KI brains showed significant RI events for short and high GC-content introns (Figures 4C and 4D). However, unlike HAP1 KO cells, we also observed a preference for weak 5' and 3' splicing sites among significant events (Figures 4E–4H and S5G), which may reflect competition for reduced PPIL1 protein between strong and weak splicing sites. Profiling of misspliced genes revealed protein translation, RNA processing, and DNA damage response as the most significantly disturbed modules (Figures 4I, S5H, and S5I), whose disruptions are major causes of cerebellar ataxia (Synofzik et al., 2019). Moreover, genes involved in axon development and cell cycle were also significantly affected (Figure 4I), reinforcing the phenotypes observed in KI brains.

PPIL1 catalyzes the isomerization of PRP17 Gly94-Pro95 95 *in vitro*

Recent cryo-EM structures allowed for detailed analysis of proline isomerases within the MSC (Bertram et al., 2017; Fica et al., 2019; Haselbach et al., 2018; Yan et al., 2015a; Zhan et al., 2018; Zhang et al., 2017; Zhang et al., 2018; Zhang et al., 2019), six of which were evident in one or more MSC complexes (Table S4). However, only for PPIL1 was it possible to identify a Pro from an adjacent protein within the enzymatic pocket, where we identified Gly94-Pro95 of PRP17 within the B^{act}, C, C*, P, and ILS complexes (Fica et al., 2019; Zhan et al., 2018; Zhang et al., 2017; Zhang et al., 2018; Zhang et al., 2019), conserved from *S. pombe* (Yan et al., 2015a) to human (Figures 5A, 5B, and S6A–S6E). This finding suggests that PRP17 may be a substrate of PPIL1 in the MSC.

Gly94-Pro95 in PRP17 occurs within an intrinsically unstructured region, between two alpha-helical domains, conserved from *S. pombe* to human (Figure 5C). There is an adjacent residue (human Phe93 or *S. pombe* Leu67) within the S2 pocket, which likely determines substrate specificity (Davis et al., 2010; Teigelkamp et al., 1998). To test their interaction, we performed heteronuclear single-quantum coherence (HSQC) spectral analysis with ¹⁵N-labeled PPIL1, and a 13-mer PRP17 peptide (aa 89–101) containing Pro95. We confirmed that PRP17 peptide interacts with PPIL1 along its enzymatic surface (Figures 5D–5F). Using isothermal titration calorimetry assay, we defined a dissociation constant (K_D) of $111.9 \pm 4.0 \mu\text{M}$ (Figure S6F). To investigate whether PPIL1 catalyzes PRP17 isomerization, we used a PRP17 peptide (aa 89–101) with ¹⁵N, ¹³C double-labeled P95, and demonstrated the Gly94-Pro95 bond was present in both cis and trans conformations (Figures S6G and S6H). Addition of catalytic concentrations of PPIL1 accelerated the rate of proline isomerization in PRP17 peptide, evidenced by the appearance of exchange peaks in ¹H ¹⁵N H(C α)N ZZ exchange spectra (Figures 5G–5I). This was also confirmed using 2D ¹H-¹⁵N ZZ exchange spectra of a uniformly ¹⁵N labeled PRP17 peptide (aa 84–101) with catalytic concentrations of PPIL1 WT (Figure S6I). We conclude that PPIL1 is capable of catalyzing PRP17 isomerization *in vitro*.

PRP17 loss associates with pontocerebellar hypoplasia

Only a few of the >100 MSC components are associated with human disease (Lines et al., 2012; Pellagatti and Boulwood, 2017; Ruzickova and Stanek, 2017; Xu et al., 2017), so we considered genes encoding PPIL1-associated proteins as candidates for PCHM. In addition to PRP17, we found SKIP and RBM22 bound to PPIL1 (Figures S6A–S6C and

Movie S1). We thus searched our unsolved pediatric brain disease cases and identified a multiplex consanguineous family with PCHM (Family 10), also with chronic anemia and thrombocytopenia, and with a homozygous *PRP17* variant, predicting a damaging p.F502C protein change (Figures 6A, 6B, and Table S1 and S2). No further families were identified in Genematcher.

PRP17 contains a C-terminal WD40 domain, where F502 resides, which is fully evolutionarily conserved (Figures 6C and 6D). In cryo-EM MSC structure, the WD40 assumes a classical ‘7-propeller’ architecture, and associates with U2 snRNA and the U2/branch point sequence (BPS) duplex, stabilizing the catalytic site (Movie S1) (Bertram et al., 2017; Haselbach et al., 2018; Zhan et al., 2018; Zhang et al., 2017). We assessed the impact of p.F502C on protein using HA-tagged cDNA expressed in HEK293T cells and found dramatic protein destabilization, which was also confirmed in patient fibroblasts (Figures 6E–6G and S7A).

More severe than *Ppil1^{fs/fs}*, *Prp17* homozygous frameshift mice were lethal prior to E9.5 (c.277_287del11, E9.5, 0 mutant in 47 embryos, $p < 0.00001$, Binomial test). We further examined RNA splicing and cell survival in HEK293T cells after CRISPRi induced repression of PRP17 followed by expression of rescue PRP17 cDNAs (Gilbert et al., 2013). Both Atg4d and Evi5l minigene reporters showed higher intron retention levels after *PRP17* knockdown, rescued by WT but not p.F502C PRP17 (Figures 6H, 6I, S7B, and S7C). We also observed that cell viability was significantly decreased after PRP17 repression, which was almost fully rescued by WT but only slightly by p.F502C cDNA (Figure 6J). These results suggest that p.F502C impairs PRP17’s function within the MSC in a fashion similar to PPIL1 patient variants.

PPIL1 mediated proline isomerization of PRP17 is not required for function

Given PPIL1 and PRP17 are both essential for embryonic development, and form an active PPIase-substrate pair, we hypothesized that catalyzed isomerization of PRP17 Gly94-Pro95 by PPIL1 is required for function. First, to rule out an effect of PPIL1 outside the spliceosome in the brain, we knocked in PPIL1 p.R131Q in mouse, since our results showed that this substitution selectively prevents its binding to SKIP, which recruits PPIL1 to the spliceosome (Wang et al., 2010). Homozygous *Ppil1^{R131Q/R131Q}* mice showed perinatal lethality, microcephaly, and evidence of neurodegeneration in a fashion similar to *Ppil1^{A99T/A99T}* (Figures 6K–6N and S7D–S7F). Selected splicing defects identified in *Ppil1^{A99T/A99T}* brains were also confirmed in *Ppil1^{R131Q/R131Q}* brains (Figures 6O and 6P). Although we observed a slightly reduced PPIL1 protein (~ 30%) in *Ppil1^{R131Q/R131Q}* embryos (Figures S7D and S7E), this is not sufficient to cause PCHM since heterozygous *Ppil1^{A99T/+}* showed even a higher reduction (~ 40%) but did not show any phenotype (Figures S2F and S2G). Together, we conclude that PPIL1 mediates its effect in the brain by subserving its role in the spliceosome.

Second, we generated two additional knockin mouse lines: isomerase-inactive PPIL1 p.Arg55Ala (Davis et al., 2010; Zhang et al., 2013; Zydowsky et al., 1992), and non-isomerizable PRP17 p.Pro95Ala. We reasoned that if isomerization catalysis is crucial, these mutations should phenocopy patient mutations. Surprisingly, we observed no phenotype in

either homozygous mutant: both *Ppil1*^{R55A/R55A} and *Prp17*^{P95A/P95A} were viable, fertile, and showed no microcephaly, cell death, or defective cortical lamination (Figures 6K–6N). Likewise, splicing defects were not observed in *Ppil1*^{R55A/R55A} or *Prp17*^{P95A/P95A} mice (Figures 6O and 6P). To confirm these results in vitro, we performed rescue assays in cultured cells by re-expressing either p.R55A PPIL1 or p.P95A PRP17. We found both mutants rescued proliferation and splicing defects as well as WT (Figures 6H–6J and S7G–S7J). Thus, while PPIL1 is capable of catalyzing PRP17 isomerization, and both are required for RNA splicing and mutated in human brain disease, their enzymatic interaction is not an essential part of the function of either protein. This data suggests the two proteins maintain a scaffolding rather than an enzyme-substrate interaction.

DISCUSSION

Here, we report that biallelic, partial loss-of-function mutations in PPIL1 and PRP17, encoding two core spliceosomal components, disrupt RNA splicing integrity and lead to neurodegenerative pontocerebellar hypoplasia with microcephaly in human and mouse. The reported patients showed severe congenital microcephaly and simplified cortical gyri, which are rarely observed in other reported PCH types. We described this unique form of PCH as a new clinical entity PCHM, wherein spliceosome genes are the major contributors. Thus, our study highlighted the essential role of global splicing integrity in brain development and neurodegeneration, and uncovered a new pathway and mechanism underlying this heterogeneous group of degenerative brain disorders.

In general, clinical severity correlated with degree of impairment of protein stability or function by different patient variants, although T107A only reduced SKIP binding moderately, yet the affected children were severely affected, suggesting a potential unexplored mechanism or possible environmental contributions.

PPIL1 and PRP17 form an active enzyme-substrate pair in the spliceosome, and both are required for RNA splicing and neuronal survival. Surprisingly, our results showed PPIL1-mediated isomerization of PRP17 was not critical for their functions in splicing and neuronal survival, thus revealing a predominant non-enzymatic function of a spliceosome isomerase. Previous in vitro work also suggested that the enzymatic activity of PPIL1 is not required for splicing of selective pre-mRNA substrates (Adams et al., 2015). In line with this, only trans PRP17 G94-P95 was observed in MSC structures reported to date (Figures S7K and S7L). In the spliceosome, PPIL1 interacts with PRP17, RBM22, and SKIP. RBM22 is an RNA interacting protein, grasping the 5' intron right after the 5'SS region where U6 snRNA hybridizes (Bertram et al., 2017; Haselbach et al., 2018; Zhan et al., 2018; Zhang et al., 2017), whereas the PRP17 WD40 domain binds to the intron branching point/U2 duplex (Movie S1). Both N-terminal SKIP and PRP17 are intrinsically disordered and undergo disorder-order transition upon PPIL1 binding (Wang et al., 2010; Zhang et al., 2017; Zhang et al., 2018). We propose that PPIL1 stabilizes these structures, allowing the MSC to function as a 'torque wrench' to bend 'challenged' introns to bring the 5'SS and the branching point into proximity. Loss of PPIL1 may reduce the ability to 'torque' the more rigid introns, which would explain the primary impacts on short and high GC content introns.

Although mutations in MSC genes had been linked to several types of diseases such as cancer and autosomal-dominant retinitis pigmentosa (Nik and Bowman, 2019; Scotti and Swanson, 2016; Singh and Cooper, 2012), our study is, to our knowledge, the first to connect MSC gene mutations and global splicing integrity to neuronal survival and neurodegeneration.

Why do mutations in these ubiquitously expressed spliceosomal genes lead to brain-specific disease? In our mouse model, apoptosis was limited to postmitotic neurons in homozygous KI mice, strikingly different from other microcephaly models which affect mitosis and survival of neural progenitors or show premature neurogenesis (Gruber et al., 2011; Insolera et al., 2014; Silver et al., 2010). Moreover, defects were observed across the body of compound heterozygous *Ppil1*^{A99T/fs} mice. These suggest a distinct mechanism in PCHM and also reveals a higher susceptibility of neurons to global splicing perturbation. Alternatively, the developing brain expresses longer genes with more AS (Lipscombe and Lopez Soto, 2019; Raj and Blencowe, 2015; Yeo and Burge, 2004), which might render neurons more susceptible. Patient mutations may affect some neural-specific splicing events critical for neuronal survival (Lin et al., 2020). Postmitotic neurons might accumulate higher levels of misspliced mRNA, impacting protein production or accumulating toxic or unfolded proteins. Loss of *PPIL1* predominantly impacted AS of brain-expressed or brain-disease genes, involved in protein translation, DNA repair, and noncoding RNA processing, whose disruptions are the main causes for degeneration in cerebellar ataxia. Moreover, we further found evidence for DNA double-strand breaks with upregulated p53 and CC3 expression, consistent with accumulated transcriptional R-loops (Costantino and Koshland, 2018), although the exact mechanism remains to be explored. All these suggest a potentially shared mechanism of neurodegeneration underlying several genetic forms of PCH.

STAR+METHODS

RESOURCE AVAILABILITY

Lead Contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Joseph G. Gleeson (jogleeson@ucsd.edu).

Materials Availability—This study did not generate new unique reagents.

Data and Code Availability—The raw RNA_seq data related to this manuscript, including human HAP1 cells and mouse E14.5 brain samples, has been deposited on SRA under accession number PRJNA669300 (<https://www.ncbi.nlm.nih.gov/sra>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human subjects—We studied patients from 10 unrelated families (Figures 1A and 6A). Information about gender, age, and health status are listed in Table S1. All work with patients was approved by the UCSD IRB protocol 140028 or local protocols, and performed according to accepted guidelines. All patients and/or parents/guardians signed a consent

form for participation. All mutations were confirmed with Sanger sequencing according to the base change and inheritance within the family.

Animals—All mice used were maintained on a C57BL/6 background and bred under standard group housing laboratory conditions with 12 hours light/dark cycle and free access to food and water. Age and number of mice used for each experiment are detailed in the figure legends. Sex of embryos used was not tested. All work with mice was performed in accordance with UCSD IACUC protocol S15113. To generate mutations in mice, the mixture of gRNA (0.6 μ M), Cas9 protein (0.6 μ M, NEB, #M0646T), and single-strand DNA oligo (10 ng/ μ l, only for knockin) was injected to mouse zygotes at UCSD Transgenic Mouse Core, offspring genotyped by PCR Sanger sequencing. Mice with correct genotypes were backcrossed with C57BL/6J WT mice for at least two generations before breeding to generate homozygous mice for analyzing phenotypes.

To produce Ppil1 knock-out mice (1 bp deletion, c.302delC; NM_026845.4), gRNA targeting GTCTGGTCCTGCGTTGGCCA was transcribed and purified as described previously (Ran et al., 2013). For the generation of patient mutation knockin mice in Ppil1^{P.A99T}, single-strand DNA oligo (TGCCCTTCATGCTCTTCTCTCTCCTTATGTCCTCCAGGGGCTGGGATTCTCACGATGCCAACGCAGGACCAGACACCAATGGCAGCCAGTTCTTTGTGACC) was co-injected with gRNA and Cas9 protein.

To generate Ppil1 N-terminal HA epitope knockin mice, synthesized crRNA (0.6 μ M) targeting GATACCTTCGCTCAGCATGG was co-injected with tracrRNA (0.6 μ M, IDT DNA), Cas9 protein, and single-strand repair DNA (CCGGGTTAACTCCGCCGGAAGT AGTGATTGCTAGCGGGGGGATACCTTCGCTCAGCATGTACCCATACGATGTTCC AGATTACGCTCTCTGGCGGCGATTCCCCCAGACACCTGGCAGCCGCCAACGTCT ACCTGGAGACTAGGTGAG).

To generate patient mutation Ppil1^{P.R131Q} knockin mice, synthesized crRNA targeting TCCCTATACCCTGGCACACT was co-injected with tracrRNA, Cas9 protein, and single-strand repair DNA (GGTCCTGGGAGTTTGTTCACCATGCCACTCGATTACCATCCCTATACCC TGGCACACTTGTCCAAAATAGTATGCTTGCCGTCCAGCCATTGCGTGGGGGCCA GGGTCACAAAGAAC).

To produce Prp17^{P.P95A} knockin mice, synthesized crRNA targeting TTCCTTATAT CGTTGCAGTT was co-injected with tracrRNA, Cas9 protein, and single-strand repair DNA (GGATTAGAGTTGAAAATACATTGTAATTCAGGATCCTTCTTTTCCTTCCTTA TATCGTTGCAGTTTGGAGCAGAAAATCCCTTTCGAACACAGCAAATGGCTGCCCTA GAAATATGCTTCTGGGTATGCAGAGCCAGC). Besides Prp17^{P.P95A} knockin mice, we also got a Prp17 frameshift mouse (11 bp deletion, c.277_287delTTTGGACCAGA; NM_027879.2) and was bred to homozygosity after back-crossing with WT mice.

To generate Ppil1^{P.R55A} knockin mice, synthesized crRNA (0.6 μ M) targeting TGAAGTCCTTGATGATCCTG was co-injected with tracrRNA (0.6 μ M, IDT DNA), Cas9

protein, and single strand repair

```
DNA(GTCATTGTCCTGGAGCTATACTGGAAGCATGCGCCAAGACCTGCAAGAAC
TTCGCGGAGCTGGCTCGGCGGGGCTACTACAATGGCACCAAGTTTCACGCGATCA
TCAAGGACTTCATGATCCAAGGCGGCGACCCGACAGGCACAGGTACACTTAAGCC
ACCATTGGGGAGGAACTGGGTGGTAAGGCAGCCACAGCT).
```

Mammalian Cells—Dermal punch biopsy was obtained under UCSD IRB protocol 171094, patients underwent sterile 0.5cm biopsy, which was mechanically dissociated and then cultured in 20% FBS in DMEM and 100U/ml penicillin-streptomycin until confluent as described (Vangipuram et al., 2013). Cells at low passage were used for protein expression analysis. HEK293T were cultured in DMEM supplemented with 10% FBS, 2mM L-glutamine and 100U/ml penicillin-streptomycin. Mouse embryonic fibroblast (MEF) cells were isolated from E13.5 embryos using mouse embryonic fibroblast isolation kit (ThermoFisher, #88279) and cultured in DMEM supplemented with 10% FBS, 2mM L-glutamine and 100 units/ml penicillin-streptomycin on gelatin-coated dishes. PPIL1 knockout HAP1 cells was generated in Horizon using the CRISPR/Cas9 system, and carries a 22 bp deletion in the first exon (22 bp deletion, c.28_49del, NM_016059). HAP1 cells were grown in Iscove's Modified Dulbecco's Medium (IMDM) with 10% FBS and 100 units/ml Pen/Strep. All cells used were tested negative for mycoplasma.

METHOD DETAILS

Analysis of patient phenotype—Patients were recruited as part of a multiyear effort to identify pedigrees showing multiple affected children with neurodegenerative or neurodevelopmental phenotypes, in the presence of parental consanguinity, in order to identify causes of recessive pediatric brain disease. Families were recruited at several locations around the world including the US, UK, Egypt, Pakistan, and Turkey. Subjects underwent detailed phenotyping analysis including standard medical, genetic, and neurological evaluations, serial evaluations over the course of months to year to characterize the natural history of disease progression, pedigree analysis, exclusion of previously identified genetic syndromes through the use of the London Dysmorphology Database and OMIM, followed by brain MRI or CT scan to evaluate for structural defects, and candidate gene sequencing where appropriate to exclude previously reported syndromes. Phlebotomy was performed on the entire family including all genetically informative members, for segregation analysis and linkage.

Human Brain MRI—Imaging was performed on standard clinical radiology equipment (0.5–1.5T) GE instruments, using standard T1, T2, and FLAIR settings. Hard copies of brain images were available in all cases, whereas digital files were available on a minority. This precluded quantitative analysis of brain morphology but allowed for comparison of images in the sagittal, axial and coronal orientations.

DNA extraction, whole-exome, and whole-genome sequencing—Patient DNA extraction and whole-exome sequencing libraries were performed using the Agilent SureSelect Human All Exon v2.0 (44Mb baited target) and sequenced on an Illumina HiSeq 2500 with v2 chemistry (Read Length: 151). Variant calling and filtering were

performed using in-house software with Annovar, Variant Effect Prediction software to define population-specific allele frequencies from 1000 Genomes, the Greater Middle East Variome, dbSNP, and gnomAD. Variants were prioritized according to allele frequency, conservation, and predicted effects on protein function.

Variant prioritization—Variant calling and filtering were performed following an established exome sequencing pipeline (Lee et al., 2019). Identified variants were filtered out if not consistent with recessive monogenic inheritance, if the minor allele frequency (MAF) of gnomAD was $>1:10,000$, if MAF of local cohort was $>1:1,000$, if not moderate or high impact, if CADD PHRED score ≥ 20 , or if not predicted as damaging by either SIFT, PolyPhen, or MutationTaster.

Sanger sequencing—Primers for Sanger sequencing were designed using the Primer3 program (U. Massachusetts) and tested for specificity using the Alamut Visual 2.7.1 software. PCR products were treated with Exonuclease I (Fermentas) and Shrimp Alkaline Phosphatase (USB Corp) and sequenced using the Big Dye terminator cycle sequencing kit v.3.1 (Applied Biosystems) on an ABI DNA analyzer (Applied Biosystems). Sequence data were analyzed using Snapgene software.

PPIL1 protein expression and purification—Full-length PPIL1 (GenBank NM_016059.4) open reading frame was cloned into NdeI/XhoI sites in pET22b expression vector. Plasmids were transformed into BL21(DE3) E. coli cells, grown at 37 °C in 2YT media (5 g/l NaCl, 10 g/l yeast extract, 16 g/l tryptone), or M9 minimal media supplemented with 0.05% w/v ^{15}N NH_4Cl (for ^{15}N labelled protein), with 100 $\mu\text{g/ml}$ ampicillin. Protein expression was induced using 1 mM isopropyl β -D-1thiogalactopyranoside (IPTG) at OD_{600} 0.5–0.8 and subsequently incubated at 18 °C overnight. PPIL1 protein was purified from cell lysate using a 1 ml Ni-NTA column (GE Healthcare) and eluted using an imidazole gradient (10 mM to 500 mM imidazole, 0.5 M NaCl, 20 mM sodium phosphate). Purity and identity of purified proteins were confirmed using SDS-PAGE Western analysis with an anti-PPIL1 antibody, and mass spectrometry.

Protein aggregation assay—Protein unfolding and aggregation were measured over a temperature gradient using an Optim machine (Unchained Labs). Protein unfolding was assessed using the barycentric mean wavelength of intrinsic protein fluorescence. Fluorescence was excited using a laser at 266 nm and emission monitored from 280 nm to 450 nm. Protein aggregation was detected by measuring static light scattering at 266 nm. Assays were carried out in PBS buffer (pH 7.4).

Immunoprecipitation assay and western blotting—HEK293T cells were seeded into 6-well plates and transfected with indicated plasmids using Lipofectamine 2000. 36 h after transfection, cells were lysed in RIPA buffer with protease inhibitor cocktail (Roche Applied Science, 11836170001). Cell lysates were centrifuged at 14,000g for 15 min at 4 °C. 45 μl supernatant was mixed with 15 μl 4 \times SDS-loading buffer and further heated at 95 °C for 2 min as total lysates. The remaining supernatant was incubated with 10 μl prewashed anti-FLAG M2 magnetic beads (Sigma-Aldrich, M8823) for 3 hours at 4 °C. The beads were washed four times with lysis buffer and eluted in 40 μl 2 \times SDS-loading buffer.

Total lysates and immunoprecipitates were further separated by SDS-PAGE and analyzed by immunoblotting. Primary antibodies used include mouse anti-Flag M2 (1:10,000, Sigma-Aldrich, F1804), mouse anti-SKIP (1:1,000, Santa Cruz, sc-393856), mouse anti-beta-actin (1:1,000, Santa Cruz, sc-47778), rabbit anti-CDC40/PRP17 (1:2,000, Abcam, ab175924) and rabbit anti-PPIL1 (1:2,000, Proteintech, 15144-1-AP).

SKIP protein expression and purification—SKIP 59–129 was cloned into pGEX-6P1 expression vector (linearised using Sall and NotI restriction enzymes) using In-Fusion HD cloning kit (Clontech). The vector was transformed into BL21(DE3) Escherichia coli cells and grown at 37 °C in 2YT media (100 µg/ml ampicillin). SKIP 59–129 expression was induced with 1 mM isopropyl β-D-1thiogalactopyranoside (at OD₆₀₀ 0.5–0.8) for three hours at 37 °C. 1 ml glutathione sepharose columns (GE Healthcare) were used to purify GST-SKIP 59–129 from cell lysates and protein was eluted with a 10 ml glutathione injection (10 mM glutathione, 50 mM Tris-HCl pH 7.4).

Surface plasmon resonance (SPR) assay—Anti-GST antibodies were immobilized on a CM5 chip (GE Healthcare) using an amine coupling reaction, in 100 mM sodium acetate buffer (pH 5.6). The chip surface was activated using 35 µl, 0.05 M N-hydroxysuccinimide/ 0.2 M N-ethyl-N'-(dimethylaminopropyl) carbodiimide injections (GE Healthcare amine coupling kit). 20 µl anti-GST antibody (GE healthcare, 27457701) was injected at 30 µg/ml and unreacted material was subsequently eluted with 40 µl 1 M NaCl. Unreacted sites were capped using 35 µl 1 M ethanolamine.HCl pH 8.5. Amine coupling was performed in 100 mM sodium acetate running buffer (pH 5.6). N-terminal GST tagged SKIP 59–129 protein was injected across the chip surface to allow immobilization on anti-GST antibodies. In order to measure binding, PPIL1 proteins were injected across the chip surface (50 µl/min, 2.5 minutes) in PBS, 0.05 % v/v IGEPAL running buffer. Experiments were carried out using Biacore 3000 system at 25°C and the data were analyzed using Biacore BiaEvaluation software.

Nissl staining—Dissected mouse brains were fixed overnight in Bouin's solution and embedded in paraffin. Sagittal sections were collected at a thickness of 5 µm and stained with Cresyl violet after deparaffinization and rehydration. Images were taken using a Leica Aperio AT2 scanner and a Keyence BZX-700 microscope.

Immunofluorescent staining and Fluorescence in situ Hybridization—Embryos were fixed in 4% paraformaldehyde (PFA), cryoprotected in 30% sucrose and then cryosectioned for immunostaining. Primary antibodies and reagents used include: rabbit anti-CUX1 (1:100, Santa Cruz, sc-13024), rat anti-CTIP2 (1:300, Abcam, ab18465), rabbit anti-cleaved caspase3 (1:400, Cell Signaling, 9661), rabbit anti-HA (1:300, Cell Signaling, 3724), rabbit anti-P53 (1:500, Leica, P53-CM5P), rabbit anti-PAX6 (1:300, Biolegend, 901301), rabbit anti-TBR2 (1:1,000, Abcam, ab183991), Rabbit anti-γ-H2AX (1:400, Cell Signaling, 9718), Mouse anti-SATB2 (1:400, Abcam, ab51502), and Goat anti-SOX2 (1:400, R&D systems, AF2018).

Fluorescence in situ Hybridization (FISH) was performed following the manufacturer's instructions (Advanced Cell Diagnostics) of RNAscope Multiplex Fluorescent Assays

V2 kit. TUNEL staining was performed with Apoptag Fluorescein *in situ* apoptosis kit (Millipore, S7110) following the provided manual. EdU fluorescence staining was performed with Click-iT™ EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (ThermoFisher, C10420). Images were taken using a Zeiss LSM 880 confocal microscope and Keyence BZX-700 fluorescent microscope and analyzed with Adobe Photoshop and Illustrator.

RNA-sequencing and data analysis—Total RNA was extracted from cultured cells or dissected mouse tissues following the manual of RNeasy Plus Mini Kit (Qiagen), yield and quality of RNA assessed by NanoDrop (Thermo Fisher Scientific) and Agilent Bioanalyzer (Agilent Technologies), respectively, enriched by poly-A capture. Paired-end libraries were prepared according to the manufacturer's protocols (TruSeq Stranded mRNA, Illumina) and sequenced using Illumina HiSeq2500 or 4000 system (paired-end 100, Illumina). 80–100 million reads were collected for each sample.

rMATS computational analysis—FASTQ files containing RNA-seq data from WT and mutant samples were trimmed with Cutadapt(Martin, 2011), aligned to reference human hg19 or mouse (GRCm38) with GTF release M16 using STAR aligner(Dobin et al., 2013) with ENCODE standard options, and with 'end-to-end alignment type' checked as required by rMATS (Shen et al., 2014). Alternative splicing events were summarized by rMATS 3.2.5, with 'novel splice site detection' turned on. Heatmap representation of inclusion levels for each sample was plotted using R package pheatmap(Kolde and Kolde, 2015). All intron positions for mouse were downloaded as one BED file from UCSC browser. Sequences from the mouse genome file were extracted using known start and end positions with bedtools getfasta function(Quinlan and Hall, 2010). Then the length and GC-content distributions of all introns, as well as introns residing in alternative splicing events, were calculated in R ggplot2(Wickham, 2016), with significance determined by FDR <0.05 and the absolute value of inclusion level difference > 0.05. A one-sided Mann-Whitney test was performed to obtain *p*-value between each group. Sequences of 40bp in length (19bp extension towards each direction) around 5' and 3' consensus splice sites of all mouse introns as well as our splicing event introns were extracted and stacked as sequence logo plots using WebLogo(Crooks et al., 2004). Splice sites strength was calculated using maxentropy python wrapper for MaxEntScan(Yeo and Burge, 2004) for both 5' and 3' sites, and scores plotted in R.

Leafcutter computational analysis—LeafCutter release 0.2.8 with STAR aligned bam files were performed according to published methods (Li et al., 2018). Intron clustering was performed by leafcutter_cluster.py with default options (maximum intron length as 100,000 bp, minimum reads in a cluster as 10, and the minimum fraction of reads in a cluster that support a junction as 0.001, respectively). Differential intron excision analysis was performed by leafcutter_ds.R with default options but --min_coverage=30 to increase specificity and --min_samples_per_intron=3 as recommended. Significance was determined by adjusted *p*-value (FDR) < 0.05 from the final output.

Sashimi plot—Sashimi plots were generated with python script `rmats2sashimiplotm`, with sorted BAM files from STAR used as inputs. Event files contain selected events extracted from rMATS outputs. Plots for different splicing types were specified by `-t` argument.

Enrichment analysis for misspliced genes in diseases—rMATS output produced lists containing the genes of significant events (misspliced genes) and genes in non-significant events (un-misspliced genes). Brain AS genes ($n=16052$) derived from (Yan et al., 2015b), OMIM genes associated with neurodevelopmental disorders ($n=2755$), cancer ($n=589$), cardiac/heart disease ($n=446$), and immune disorders ($n=386$) derived were requested from NCBI.

A 2×2 contingency table was generated for each disease gene list and the number of genes was calculated for inclusion or exclusion in the misspliced and unmisspliced genes, respectively, or calculated with 95% confidence interval. p-values were generated using Fischer's Exact test and corrected for multiple tests with the Bonferroni method.

Pathway and Process Enrichment Analysis—Enrichment of Gene Ontology (GO) Biological Processes and KEGG pathways was carried out with KOBAS 2.0 as previous described (Xie et al., 2011). The list of genes ($n = 2134$) with altered AS in the mutant mouse brains were created from all the significant AS events in rMATS analysis. All expressed genes ($n = 15169$) in E14.5 mouse brain hemisphere were obtained from RNA-seq data with RPKM >1.0 and used as a background list. Networks of enriched pathways were generated by Metascape (Zhou et al., 2019), with ontology sources: GO Biological Processes, KEGG Pathway, Reactome Gene Sets, and CORUM. Terms with a $p < 0.01$, a minimum count of 3, and an enrichment factor > 1.5 , grouped into clusters based on membership similarities.

Semi-quantitative RT-PCR—Total RNA was extracted from cultured cells or tissue with RNeasy Plus Mini Kit (Qiagen), according to the manufacturer's instructions. 1 μg RNA was reverse transcribed with cDNA Synthesis Kit (Maxima First Strand cDNA Synthesis Kit for RT-qPCR, with dsDNase, ThermoFisher) following the provided manual. Minus reverse transcription (RT) negative control was added for each sample to check for DNA contamination. Negative control for PCR was included for each experiment. Primers sequences used were listed in Table S5.

Splicing reporter assay—Splicing minigene constructs were generated as previously reported (Kishore et al., 2008). Briefly, DNA fragment containing 3' intron-exon-intron-exon-5' intron was amplified by PCR using mouse genomic DNA as a template, which was further cloned into pSpliceExpress reporter vector using gateway recombination cloning technique. For splicing analysis, cells were transfected with pSpliceExpress plasmids and cultured for additional 36–48 hours before the extraction of total RNA. RNA was then reversed transcribed and semi-quantitative RT-PCR was performed to check the splicing of the introns. Primer sequences were: CTCTCTACCTGGTGTGTGGG (forward), and AGTGCCAAGGTCTGAAGGTC (reverse). *GADPH* was amplified as control for each experiment.

Purification of uniformly ^{15}N labeled PRP17 peptide—His-SUMO-PRP17 (18 mer: T84-T101, TYETMFAPEFGPENPFRT) was cloned into NcoI/XhoI sites in pET-28b expression vector, transformed into BL21(DE3) E. coli cells, grown in 5 ml LB medium at 37°C for 6 hours and 500 μl cultured LB medium was then added to 100 ml M9 minimal media supplemented with 0.05% w/v ^{15}N NH_4Cl for overnight culture at 37 °C. Cells were further transferred to 4 L ^{15}N minimal medium. Protein expression was induced using 1 mM IPTG at OD_{600} 0.7–0.8 and cells were subsequently incubated at 37 °C for 8 hours. The His-tagged recombinant protein was purified from cell lysates using Ni-NTA agarose (GE healthcare) and eluted protein was further dialyzed into SUMO cleavage buffer (25mM Tris-HCl, 100 mM NaCl, PH=8.0). Purified protein was cleaved by SUMO protease (MC-LAB, SP-100) at 30 °C for 6 hours. After cleavage, His-SUMO and SUMO proteases were absorbed by Ni-NTA agarose and the collected flow-through containing PRP17 peptide was loaded to reverse-phase HPLC column (WATERS, C18) with 0.1% TFA (Trifluoroacetic acid). The peptide was eluted using an increased gradient of elution buffer (90% Acetonitrile, 0.1% TFA, and 10% H_2O). Purified ^{15}N labeled PRP17 peptide was collected and further lyophilized. Purity and identity of purified peptide were confirmed using peptide SDS-PAGE with 16.5% Mini-PROTEAN Tris-Tricine Gel (BioRad, Inc), MALDI-TOFMS analysis for molecular weight, and mass spectrometry.

$^1\text{H}^{15}\text{N}$ HSQC of PPIL1— $^1\text{H}^{15}\text{N}$ heteronuclear single quantum coherence (HSQC) spectra of ^{15}N labeled PPIL1 were recorded in the presence and absence of PRP17 peptide (Bio-FAPEFGPENPFRT- NH_2 ; purchased from Peptide Synthetics, Inc). PPIL1 concentration was 80 μM and PRP17 peptide was titrated in at 0–5 molar equivalents in 10 mM sodium phosphate, 100 mM NaCl, 5% D_2O at pH 6.5. Spectra were collected on a Bruker 600 MHz NMR spectrometer equipped with a quadruple-resonance QCI-P cryo-probe (QCI-P CP). Resonances were identified using the published assignment of PPIL1 (Stegmann et al., 2010; Xu et al., 2005). Average chemical shift perturbations were calculated as described elsewhere (Hewitt et al., 2017).

$^1\text{H}^{15}\text{N}$ H(C α)N ZZ exchange spectra of PRP17 peptide— $^1\text{H}^{15}\text{N}$ -H(C α)N ZZ exchange spectra (based on spectra used by previous study (Dujardin et al., 2015)) were acquired of 500 M PRP17 (residues 89–101 PRP17, Ac-FAPEFGPENPFRT- NH_2 , ^{15}N , and ^{13}C labeled Pro95) in the presence and absence of catalytic concentrations of PPIL1 (5 μM). The sample buffer used was PBS buffer (pH 7.4), 5% D_2O and spectra were acquired using a 950 MHz triple resonance spectrometer equipped with a TXO triple resonance cryo-probe (TXO-CP).

$^1\text{H}^{15}\text{N}$ ZZ exchange spectra of uniformly ^{15}N labeled PRP17 peptide— $^1\text{H}^{15}\text{N}$ ZZ exchange spectra were acquired of uniformly ^{15}N labeled PRP17 peptide (residues 84–101 PRP17; 400 concentrations of PPIL1 (4 120($\times 2$), 150, 200, 250($\times 2$), 350, 450, 600 and 750 ms. The sample buffer used was: 25 mM sodium phosphate buffer, 100 mM NaCl, 1 mM dithiothreitol, 5% D_2O at pH 7.0. Spectra were acquired on a Bruker 950 MHz NMR spectrometer with a TXO triple resonance cryo-probe (TXO-CP).

Isothermal Titration Calorimetry (ITC) assay—PRP17 peptide (2 mM) was titrated into PPIL1 WT protein (40 μ M), in PBS buffer (pH 7.4). Experiments were carried out using Microcal ITC 200 calorimeter at 25 °C. PRP17 titrations were carried out using 2 μ l, 4-second injections spaced 2 minutes apart. Results were analyzed using Microcal Origin 7 software. Binding curves were fit to a one-site interaction model using a fixed stoichiometry ($n = 1$), which is recommended for low-affinity interactions (Turnbull and Daranas, 2003).

Assignment of cis and trans resonances, PRP17 peptide—A ^1H - ^{13}C heteronuclear single quantum coherence (HSQC) spectrum of PRP17 peptide (PRP17 89–101; ^{13}C and ^{15}N labeled pro95) were recorded with 500 μ M peptide in PBS (pH 7.4), 5 % v/v D_2O using a Bruker 750 MHz NMR spectrometer equipped with a triple-resonance TCI triple resonance cryoprobe (TCI-CP). Cis and trans PRP17 Gly94P-ro95 peptide bond assignment was based on the ^{13}C chemical shift for C_γ and C_β resonances, as reported (Shen and Bax, 2010).

CRISPRi knockdown assay in HEK293T cells—Empty CRISPRi plasmid (PX330-U6-2XBsmBI-gRNA-CBh-dCas9-KRAB-T2a-Puro) was generated on the modified PX330 with 2 \times BsmBI gRNA cloning sites. dCas9-KRAB-T2a-Puro was amplified from vector pLV-hU6-sgRNA-hUbc-dCas9-KRAB-T2aPuro (Addgene #71236) and cloned inside PX330 to replace original WT Cas9. gRNAs targeting PRP17 or scramble gRNA was further cloned between 2XBsmBI sites. CRISPRi plasmids containing *PRP17* or scramble gRNAs were co-transfected into HEK293T cells with either empty pcDNA3 or PRP17 cDNAs. 24 hours after transfection, cells were treated with 5 μ g/ml puromycin for 36 hours to kill untransfected cells and then cultured in medium without puromycin for additional 24–36 hours before used for RNA extraction or Resazurin cell viability assay.

Resazurin (cell viability/proliferation) assay—Cultured cells were treated with 20% Resazurin (R&D, AR002) in the medium for 2 hours at 37 °C. 100 μ l resazurin medium was further transferred to a well in 96-well plate. Fluorescence was read using Ex544nm/Em590 nm by Spectramax M5 microplate reader (Molecular Devices) and the final reading was subtracted from the background control (Resazurin in medium without cells).

Splicing rescue assay in HAP1 cells—WT and PPIase-inactive (p.R55A) PPIL1 CDS with a stop-codon was cloned into Doxycycline (DOX)-inducible pINDUCER20 expression vector, using Gateway cloning system (ThermoFisher). Lentivirus was generated by co-transfecting pINDUCER20 (empty, WT PPIL1, and R55A PPIL1, respectively), pMD2.G envelope plasmid (Addgene 12259) and psPAX2 packaging plasmid (Addgene 12260) into HEK293T cells, using Lipofectamine 2000 (ThermoFisher Scientific). The viral supernatant medium was collected at 48 and 72 hours, respectively, and then pooled and concentrated 100 \times using Lenti-X Concentrator (Clontech, # 631232). WT and PPIL1 knockout HAP1 cells were infected with concentrated lentivirus overnight in the presence of 5 μ g/ml polybrene. 72 hours after infection, cells were selected with 1 mg/ml G418 for 2 weeks. Stable HAP1 cells were further treated with different concentrations of DOX (0, 0.1, and 0.5 μ g/ml, respectively) for 72 hours and then lysed in RIPA buffer. Western blot was then applied to test the expression level of DOX-induced WT and

R55A PPIL1. For splicing minigene assay, stable HAP1 cells were first cultured with 0.1 μ g/ml DOX for 5 days and then transfected with the minigene splicing plasmid using lipofectamine 3000 (ThermoFisher Scientific) in the presence of DOX. Total RNA was extracted from transfected HAP1 cells 48 hours later and then reverse transcribed followed by semi-quantitative RT-PCR. For checking the splicing of endogenous genes, stable HAP1 cells were cultured in the presence of 0.1 μ g/ml DOX for 7 days and then lysed for total RNA extraction, reverse transcription and semi-quantitative RT-PCR.

QUANTIFICATION AND STATISTICAL ANALYSIS

Unless specifically stated, each experiment was performed at least twice for each condition. Due to variabilities in the absolute values obtained in each experiment, for some assays, data from one experiment is presented and noted in the figure legend. For normally distributed data, unpaired t-tests were performed using Graphpad Prism 7 and *p* values were labeled in the figure panels with ns ($p > 0.05$), *($p < 0.05$), **($p < 0.01$), ***($p < 0.001$), and ****($p < 0.0001$), and the exact values were shown in either panels or figure legends. Other statistics used include one-way ANOVA test, non-parametric Mann-Whitney test, Wilcoxon test, and Fischer's Exact test, and were described in the figure legend and methods.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This work was supported by SFARI 51486313, NIH R01NS048453, R01NS09800, QNRF NPRP 6-1463-3-351 (to J.G.G.), UMIHG008900/Broad Institute Center for Mendelian Genomics U54HG006504/Yale Center for Mendelian Disorders, N01 2682017000061-0-26800029 to CIDR for genotyping. J.G.G. is an investigator with the Howard Hughes Medical Institute and received support from Rady Children's Institute for Genomic Medicine. We thank Peter Jackson (Stanford) for mass spectrometry analysis, Xiang-Dong Fu, Susan Taylor, Joshua Mayfield, and Jack Dixon for comments, UCSD Mouse Transgenic Core, UCSD CTRI (UL1TR001442) for biostatistics support, UCSD Neuroscience Core (P30 NS047101) and UCSD IGM Genomics Core (#S10 OD026929). We are also grateful to the Astbury BioStructure Laboratory BioNMR Facility funded by the University of Leeds and the Wellcome Trust (094232).

REFERENCES

- Adams BM, Coates MN, Jackson SR, Jurica MS, and Davis TL (2015). Nuclear cyclophilins affect spliceosome assembly and function in vitro. *Biochem J* 469, 223–233. [PubMed: 25967372]
- Agafonov DE, Deckert J, Wolf E, Odenwalder P, Bessonov S, Will CL, Urlaub H, and Luhrmann R. (2011). Semiquantitative proteomic analysis of the human spliceosome via a novel two-dimensional gel electrophoresis method. *Mol Cell Biol* 31, 2667–2682. [PubMed: 21536652]
- Akizu N, Cantagrel V, Schroth J, Cai N, Vaux K, McCloskey D, Naviaux RK, Van Vleet J, Fenstermaker AG, Silhavy JL, et al. (2013). AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder. *Cell* 154, 505–517. [PubMed: 23911318]
- Bertram K, Agafonov DE, Liu WT, Dybkov O, Will CL, Hartmuth K, Urlaub H, Kastner B, Stark H, and Luhrmann R. (2017). Cryo-EM structure of a human spliceosome activated for step 2 of splicing. *Nature* 542, 318–323. [PubMed: 28076346]
- Bessonov S, Anokhina M, Krasauskas A, Golas MM, Sander B, Will CL, Urlaub H, Stark H, and Luhrmann R. (2010). Characterization of purified human Bact spliceosomal complexes reveals compositional and morphological changes during spliceosome activation and first step catalysis. *RNA* 16, 2384–2403. [PubMed: 20980672]

- Breuss MW., Sultan T., James KN., Rosti RO., Scott E., Musaev D., Furia B., Reis A., Sticht H., Al-Owain M., et al. (2016). Autosomal-recessive mutations in the tRNA splicing endonuclease subunit TSEN15 cause pontocerebellar hypoplasia and progressive microcephaly. *Am J Hum Genet* 99, 228–235. [PubMed: 27392077]
- Budde BS, Namavar Y, Barth PG, Poll-The BT, Nurnberg G, Becker C, van Ruissen F, Weterman MA, Fluiter K, te Beek ET, et al. (2008). tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. *Nat Genet* 0, 1113–1118.
- Cassandrini D, Biancheri R, Tessa A, Di Rocco M, Di Capua M, Bruno C, Denora PS, Sartori S, Rossi A, Nozza P, et al. (2010). Pontocerebellar hypoplasia: clinical, pathologic, and genetic studies. *Neurology* 75, 1459–1464. [PubMed: 20956791]
- Chabot B, and Shkreta L. (2016). Defective control of pre-messenger RNA splicing in human disease. *J Cell Biol* 212, 1–27.
- Costantino L, and Koshland D. (2018). Genome-wide map of R-Loop-Induced damage reveals how a subset of R-Loops contributes to genomic instability. *Mol Cell* 71, 487–497 e483. [PubMed: 30078723]
- Crooks GE, Hon G, Chandonia JM, and Brenner SE (2004). WebLogo: a sequence logo generator. *Genome Res* 14, 1188–1190. [PubMed: 15173120]
- Davis TL, Walker JR, Campagna-Slater V, Finerty PJ Jr, Paramanathan R, Bernstein G, MacKenzie F, Tempel W, Ouyang H, and Lee WH (2010). Structural and biochemical characterization of the cyclophilin family of peptidyl-prolyl isomerases. *PLoS biology* 8, e1000439.
- Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, et al. (2005). Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. *Cell* 122, 379–391. [PubMed: 16096058]
- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21. [PubMed: 23104886]
- Dujardin M, Madan V, Montserret R, Ahuja P, Huvent I, Launay H, Leroy A, Bartenschlager R, Penin F, Lippens G, et al. (2015). A proline-tryptophan turn in the intrinsically disordered domain 2 of NS5A protein is essential for Hepatitis C virus RNA replication. *J Biol Chem* 290, 19104–19120. [PubMed: 26085105]
- Evans PA, Dobson CM, Kautz RA, Hatfull G, and Fox RO (1987). Proline isomerism in staphylococcal nuclease characterized by NMR and site-directed mutagenesis. *Nature* 329, 266–268. [PubMed: 3627269]
- Fica SM, Oubridge C, Wilkinson ME, Newman AJ, and Nagai K. (2019). A human postcatalytic spliceosome structure reveals essential roles of metazoan factors for exon ligation. *Science* 363, 710–714. [PubMed: 30705154]
- Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, et al. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* 154, 442–451. [PubMed: 23849981]
- Gruber R, Zhou Z, Sukchev M, Joerss T, Frappart PO, and Wang ZQ (2011). MCPH1 regulates the neuroprogenitor division mode by coupling the centrosomal cycle with mitotic entry through the Chk1-Cdc25 pathway. *Nat Cell Biol* 13, 1325–1334. [PubMed: 21947081]
- Haselbach D, Komarov I, Agafonov DE, Hartmuth K, Graf B, Dybkov O, Urlaub H, Kastner B, Luhrmann R, and Stark H. (2018). Structure and conformational dynamics of the human spliceosomal B(act) complex. *Cell* 172, 454–464 e411. [PubMed: 29361316]
- Hewitt SH, Filby MH, Hayes E, Kuhn LT, Kalverda AP, Webb ME, and Wilson AJ (2017). Protein surface mimetics: understanding how ruthenium tris(Bipyridines) interact with proteins. *Chembiochem* 18, 223–231. [PubMed: 27860106]
- Insolera R, Bazzi H, Shao W, Anderson KV, and Shi SH (2014). Cortical neurogenesis in the absence of centrioles. *Nat Neurosci* 17, 1528–1535. [PubMed: 25282615]
- Jangi M, Fleet C, Cullen P, Gupta SV, Mekhoubad S, Chiao E, Allaire N, Bennett CF, Rigo F, Krainer AR, et al. (2017). SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. *Proc Natl Acad Sci U S A* 114, E2347–E2356. [PubMed: 28270613]

- Joseph JT, Innes AM, Smith AC, Vanstone MR, Schwartzentruber JA, Bulman DE, Majewski J, Daza RA, Hevner RF, Michaud J, et al. (2014). Neuropathologic features of pontocerebellar hypoplasia type 6. *J Neuropathol Exp Neurol* 73, 1009–1025. [PubMed: 25289895]
- Karaca E., Weitzer S., Pehlivan D., Shiraishi H., Gogakos T., Hanada T., Jhangiani SN., Wiszniewski W., Withers M., Campbell IM., et al. (2014). Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. *Cell* 157, 636–650. [PubMed: 24766809]
- Kishore S, Khanna A, and Stamm S. (2008). Rapid generation of splicing reporters with pSpliceExpress. *Gene* 427, 104–110. [PubMed: 18930792]
- Kolde R, and Kolde MR (2015). Package ‘pheatmap’. R Package 1.
- Lee S, Chen DY, Zaki MS, Maroofian R, Houlden H, Di Donato N, Abdin D, Morsy H, Mirzaa GM, Dobyns WB, et al. (2019). Bi-allelic Loss of Human APC2, Encoding Adenomatous Polyposis Coli Protein 2, Leads to Lissencephaly, Subcortical Heterotopia, and Global Developmental Delay. *Am J Hum Genet* 105, 844–853. [PubMed: 31585108]
- Li YI, Knowles DA, Humphrey J, Barbeira AN, Dickinson SP, Im HK, and Pritchard JK (2018). Annotation-free quantification of RNA splicing using LeafCutter. *Nat Genet* 50, 151158.
- Lin L, Zhang M, Stoilov P, Chen L, and Zheng S. (2020). Developmental Attenuation of Neuronal Apoptosis by Neural-Specific Splicing of Bak1 Microexon. *Neuron* 107, 1180–1196 e1188. [PubMed: 32710818]
- Lines MA, Huang L, Schwartzentruber J, Douglas SL, Lynch DC, Beaulieu C, GuionAlmeida ML, Zechi-Ceide RM, Gener B, Gillissen-Kaesbach G, et al. (2012). Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly. *Am J Hum Genet* 90, 369–377. [PubMed: 22305528]
- Lipscombe D, and Lopez Soto EJ (2019). Alternative splicing of neuronal genes: new mechanisms and new therapies. *Curr Opin Neurobiol* 57, 26–31. [PubMed: 30703685]
- Martin M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet journal* 17, 10–12.
- Namavar Y, Barth PG, Kasher PR, van Ruissen F, Brockmann K, Bernert G, Writzl K, Ventura K, Cheng EY, Ferriero DM, et al. (2011). Clinical, neuroradiological and genetic findings in pontocerebellar hypoplasia. *Brain* 134, 143–156. [PubMed: 20952379]
- Nik S, and Bowman TV (2019). Splicing and neurodegeneration: Insights and mechanisms. *Wiley Interdiscip Rev RNA* 10, e1532. [PubMed: 30895702]
- Paulsen RD, Soni DV, Wollman R, Hahn AT, Yee MC, Guan A, Hesley JA, Miller SC, Cromwell EF, Solow-Cordero DE, et al. (2009). A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. *Mol Cell* 35, 228–239. [PubMed: 19647519]
- Pellagatti A, and Boultonwood J. (2017). Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications. *Adv Biol Regul* 63, 5970.
- Quinlan AR, and Hall IM (2010). BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26, 841–842. [PubMed: 20110278]
- Raj B, and Blencowe BJ (2015). Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. *Neuron* 87, 14–27. [PubMed: 26139367]
- Rajiv C, and Davis TL (2018). Structural and functional insights into human nuclear cyclophilins. *Biomolecules* 8, 161.
- Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, and Zhang F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 8, 2281–2308. [PubMed: 24157548]
- Rappsilber J, Ryder U, Lamond AI, and Mann M. (2002). Large-scale proteomic analysis of the human spliceosome. *Genome Res* 12, 1231–1245. [PubMed: 12176931]
- Ruzickova S, and Stanek D. (2017). Mutations in spliceosomal proteins and retina degeneration. *RNA Biol* 14, 544–552. [PubMed: 27302685]
- Schaffer AE, Eggens VR, Caglayan AO, Reuter MS, Scott E, Coufal NG, Silhavy JL, Xue Y, Kayserili H, Yasuno K, et al. (2014). CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. *Cell* 157, 651–663. [PubMed: 24766810]
- Schwarz JM, Cooper DN, Schuelke M, and Seelow D. (2014). MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 11, 361–362. [PubMed: 24681721]

- Scotti MM., and Swanson MS. (2016). RNA mis-splicing in disease. *Nat Rev Genet* 17, 19–32. [PubMed: 26593421]
- Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q, and Xing Y. (2014). rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. *Proc Natl Acad Sci U S A* 111, E5593–5601. [PubMed: 25480548]
- Shen Y, and Bax A. (2010). Prediction of Xaa-Pro peptide bond conformation from sequence and chemical shifts. *J Biomol NMR* 6, 199–204.
- Shi Y. (2017). Mechanistic insights into precursor messenger RNA splicing by the spliceosome. *Nat Rev Mol Cell Biol* 18, 655–670. [PubMed: 28951565]
- Silver DL, Watkins-Chow DE, Schreck KC, Pierfelice TJ, Larson DM, Burnetti AJ, Liaw HJ, Myung K, Walsh CA, Gaiano N, et al. (2010). The exon junction complex component Magoh controls brain size by regulating neural stem cell division. *Nat Neurosci* 13, 551–558. [PubMed: 20364144]
- Singh RK, and Cooper TA (2012). Pre-mRNA splicing in disease and therapeutics. *Trends Mol Med* 18, 472–482. [PubMed: 22819011]
- Sobreira N, Schiettecatte F, Valle D, and Hamosh A. (2015). GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat* 36, 928–930. [PubMed: 26220891]
- Sorrells S, Nik S, Casey M, Cameron RC, Truong H, Toruno C, Gulfo M, Lowe A, Jette C, Stewart RA, et al. (2018). Spliceosomal components protect embryonic neurons from R-loop-mediated DNA damage and apoptosis. *Dis Model Mech* 11.
- Stegmann CM, Luhrmann R, and Wahl MC (2010). The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. *PLoS One* 5, e10013.
- Synofzik M, Puccio H, Mochel F, and Schols L. (2019). Autosomal recessive cerebellar ataxias: paving the way toward targeted molecular therapies. *Neuron* 101, 560–583. [PubMed: 30790538]
- Teigelkamp S, Achsel T, Mundt C, Gothel SF, Cronshagen U, Lane WS, Marahiel M, and Luhrmann R. (1998). The 20kD protein of human [U4/U6.U5] tri-snRNPs is a novel cyclophilin that forms a complex with the U4/U6-specific 60kD and 90kD proteins. *RNA* 4, 127141.
- Turnbull WB, and Daranas AH (2003). On the value of c: can low affinity systems be studied by isothermal titration calorimetry? *J Am Chem Soc* 125, 14859–14866. [PubMed: 14640663]
- van Dijk T, Baas F, Barth PG, and Poll-The BT (2018). What's new in pontocerebellar hypoplasia? An update on genes and subtypes. *Orphanet J Rare Dis* 13, 92. [PubMed: 29903031]
- Vangipuram M, Ting D, Kim S, Diaz R, and Schule B. (2013). Skin punch biopsy explant culture for derivation of primary human fibroblasts. *J Vis Exp*, e3779. [PubMed: 23852182]
- Wang X, Zhang S, Zhang J, Huang X, Xu C, Wang W, Liu Z, Wu J, and Shi Y. (2010). A large intrinsically disordered region in SKIP and its disorder-order transition induced by PPIL1 binding revealed by NMR. *J Biol Chem* 285, 4951–4963. [PubMed: 20007319]
- Wickham H. (2016). ggplot2: elegant graphics for data analysis (Springer).
- Will CL, and Luhrmann R. (2011). Spliceosome structure and function. *Cold Spring Harb Perspect Biol* 3, a003707.
- Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY, and Wei L. (2011). KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. *Nucleic Acids Res* 39, W316–322. [PubMed: 21715386]
- Xu C, Xu Y, Tang Y, Wu J, Shi Y, Huang Q, and Zhang Q. (2005). Backbone and side chain assignments of human Peptidylprolyl Isomerase Like 1 (hPPIL1). *J Biomol NMR* 31, 179180.
- Xu C, Zhang J, Huang X, Sun J, Xu Y, Tang Y, Wu J, Shi Y, Huang Q, and Zhang Q. (2006). Solution structure of human peptidyl prolyl isomerase-like protein 1 and insights into its interaction with SKIP. *J Biol Chem* 281, 15900–15908. [PubMed: 16595688]
- Xu M, Xie YA, Abouzeid H, Gordon CT, Fiorentino A, Sun Z, Lehman A, Osman IS, Dharmat R, Riveiro-Alvarez R, et al. (2017). Mutations in the Spliceosome Component CWC27 Cause Retinal Degeneration with or without Additional Developmental Anomalies. *Am J Hum Genet* 100, 592–604. [PubMed: 28285769]
- Yan C, Hang J, Wan R, Huang M, Wong CC, and Shi Y. (2015a). Structure of a yeast spliceosome at 3.6-angstrom resolution. *Science* 349, 1182–1191. [PubMed: 26292707]

- Yan Q., Weyn-Vanhentenryck SM., Wu J., Sloan SA., Zhang Y., Chen K., Wu JQ., Barres BA., and Zhang C. (2015b). Systematic discovery of regulated and conserved alternative exons in the mammalian brain reveals NMD modulating chromatin regulators. *Proc Natl Acad Sci U S A* 112, 3445–3450. [PubMed: 25737549]
- Yeo G, and Burge CB (2004). Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol* 11, 377–394. [PubMed: 15285897]
- Zhan X, Yan C, Zhang X, Lei J, and Shi Y. (2018). Structure of a human catalytic step I spliceosome. *Science* 359, 537–545. [PubMed: 29301961]
- Zhang X, Chen MH, Wu X, Kodani A, Fan J, Doan R, Ozawa M, Ma J, Yoshida N, Reiter JF, et al. (2016). Cell-type-specific alternative splicing governs cell fate in the developing cerebral cortex. *Cell* 166, 1147–1162 e1115. [PubMed: 27565344]
- Zhang X, Yan C, Hang J, Finci LI, Lei J, and Shi Y. (2017). An atomic structure of the human spliceosome. *Cell* 169, 918–929 e914. [PubMed: 28502770]
- Zhang X, Yan C, Zhan X, Li L, Lei J, and Shi Y. (2018). Structure of the human activated spliceosome in three conformational states. *Cell Res* 28, 307–322. [PubMed: 29360106]
- Zhang X, Zhan X, Yan C, Zhang W, Liu D, Lei J, and Shi Y. (2019). Structures of the human spliceosomes before and after release of the ligated exon. *Cell Res* 29, 274–285. [PubMed: 30728453]
- Zhang XC, Wang WD, Wang JS, and Pan JC (2013). PPIase independent chaperonelike function of recombinant human Cyclophilin A during arginine kinase refolding. *FEBS Lett* 587, 666–672. [PubMed: 23376614]
- Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, and Chanda SK (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun* 10, 1523. [PubMed: 30944313]
- Zhou Z, Licklider LJ, Gygi SP, and Reed R. (2002). Comprehensive proteomic analysis of the human spliceosome. *Nature* 419, 182–185. [PubMed: 12226669]
- Zydowsky LD, Etzkorn FA, Chang HY, Ferguson SB, Stolz LA, Ho SI, and Walsh CT (1992). Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. *Protein Sci* 1, 1092–1099. [PubMed: 1338979]

HIGHLIGHTS

- Loss of spliceosomal components PPIL1 and PRP17 occurs in pontocerebellar hypoplasia
- Modeling shows neural apoptosis and disrupted global RNA splicing integrity
- PPIL1 and PRP17 form an enzyme-substrate pair within the active spliceosome
- PPIL1 and PRP17 control splicing independent of enzyme activity




Figure 1. Biallelic mutations in *PPIL1* lead to neurodegenerative pontocerebellar hypoplasia with microcephaly (PCHM) in human

(A) The families with predicted effects of *PPIL1* variants listed above pedigree. All variants are homozygous in affected individuals, except Family 7–9, which are compound heterozygous. All pathogenic variants segregated as a recessive trait. Filled symbols: affected; p.[?]: splice donor site mutation, c.280+1G>A; square: male; circle: female; double bar: consanguinity; diagonal line: deceased. wt, reference allele; mut, patient variant allele. (B) Sagittal (top) and axial (bottom) T1-weighted brain MRIs show reduced cerebellar volume (yellow arrowhead), atrophic pons (white arrowhead) and posterior fossa fluid

accumulation (yellow arrows) indicative of cerebellar atrophy in affected individuals. Simplified gyri pattern is most apparent in the affected from Family 1 and 4.

(C) Identified PPIL1 mutations. Above: homozygous variants. Below: compound heterozygous mutations.

(D) En face view of enzymatic surface with labeled variant residues in NMR-resolved PPIL1 structure (PDB: 2K7N). All except R131 (blue) localized to the enzymatic surface. Red: duplicated region in Family 6 (A101-D106).

See also Figure S1.




Figure 2. Patient *PPIL1* mutation knockin mice exhibit PCHM-like phenotype

(A and B) Fluorescent in situ hybridization (FISH) on coronal sections of E14.5 brain cortex hybridized with *Ppil1* (A) and *Pax6* (B) probes using RNAscope. Scale bar: 50 μm.

(C and D) Coronal sections of E14.5 embryos from *Ppil1*^{HA/+} (C) and WT (D) embryos immunostained with an anti-HA antibody showing ubiquitous expression of PPIL1. CP: cortical plate. Bar: 50 μm.

(E) *Ppil1*^{fs/fs} mouse embryos showed reabsorption at E9.5. Bar: 2 mm.

(F and G) Homozygous patient variant p.A99T knockin mouse with microcephaly at E18.5.


(H-M) Nissl stained sagittal sections of E18.5 *Ppil1*^{A99T/A99T} brains, magnified for dashed regions in the cerebral cortex and cerebellum.

(N) E18.5 *Ppil1*^{A99T/A99T} cortex (coronal) shows reduced thickness but with intact lamination based upon immunostaining against CUX1 (upper layer neurons) and CTIP2 (lower layer neurons).

(O) Reduced density of cortical CUX1⁺ and CTIP2⁺ neurons in E18.5 *Ppil1*^{A99T/A99T} cortex. n = 4 mice/genotype. Mean ± s.d.; p = 0.0003 CUX1⁺ cells; p < 0.0001 CTIP2⁺ cells; two-tailed unpaired t-test.

Scale bar: 1 mm in H and K; 50 μm in I, J, and L–M.

See also Figure S2.



(W and X) Reduced density of cortical PAX6+ neural stem cells and TBR2+ intermediate progenitor cells in E13.5 and E14.5 cortex. Mean \pm s.d.; $p = 0.0029$ E13.5 PAX6+, $p = 0.0002$ E14.5 PAX6+; $p < 0.0001$ E13.5 TBR2+; $p = 0.0008$ E14.5 TBR2+; two-tailed unpaired t-test.

Scale bar: 50 μ m.

See also Figures S2 and S3.




Figure 4. Global splicing integrity defects in *Ppil1*^{A99T/A99T} developing brain
 (A) Impact of p.A99T mutation on five major types of AS events detected with rMATS in E14.5 brain hemispheres (3 KI vs. 3WT). A3SS was most impacted, followed by SE, RI, MXE, and A5SS.
 (B) Minigene splicing reporter assays in transfected *Ppil1*^{A99T/A99T} mouse embryonic fibroblasts show higher intron retention levels in mutant cells for both Atg4d and Evi5l.
 (C and D) Distribution of differential splicing identified by rMATS in KI or control, based upon intron length and GC content. Introns with short length or high GC content show

significantly retained higher in Ppil1 KI brains. All introns represent all identified introns from mouse reference genome. p-value: Wilcox test.

(E-H) Splice-site strength analysis of 5'SS and 3'SS in all introns (All, gray), non-significant A5SS or A3SS events (Non-sig, green), and significant A5SS or A3SS events (Sig, red) identified by rMATS. The 5'SS and 3'SS strength show lower maximum entropy for choice points that were significantly different in KI compared with control. p-value: Wilcox test.

(I) Metascape visualization of enriched networks and pathways among all misspliced genes in E14.5 Ppil1^{A99T/A99T} brains (n = 2134 misspliced genes), showing several key modules represented including “mRNA metabolic process” among others.

See also Figures S4 and S5 and Table S3.




Figure 5. PPIL1 P95 is positioned in the enzymatic pocket of PRP17 in the activated spliceosome (A and B) Cryo-EM structure of human spliceosome C* complex (PDB: 5XJC) shows an N-terminal loop of PRP17 (cartoon in purple) bound to PPIL1 (teal) enzymatic surface with Pro95 buried inside the S1 enzymatic pocket. (C) Protein sequence alignment of PRP17 from 6 species shows an evolutionarily conserved Gly-Pro (G-P) motif in PRP17. * stands for identical residues, : indicates similar residues. (D) Overlaid ^1H - ^{15}N HSQC spectra of PPIL1 with PRP17 peptide titrations (0–5 molar equivalents, aa 89–101: FAPEFG[P]ENPFRT). Specific resonance shifts or broadening

beyond detection indicates specific binding of PRP17 to PPIL1. Inset: Examples of PPIL1 resonance changes that shift (arrowhead), broaden beyond detection (open arrowhead) or were unchanged (arrow) as a result of PRP17 titration.

(E) Average chemical shift perturbations of PPIL1 residues upon titration with PRP17. Gray: shifted resonances. Red: broadened beyond detection resonances. Solid or dashed lines: shifts >1 or >2 SD above mean, respectively.

(F) Space-filling model of PPIL1 (PDB: 2X7K) showed significantly perturbed residues upon PRP17 peptide binding. Red: residues broadened beyond detection, Orange: residues >2 SD, Yellow: residues >1 SD above mean. Residues affected in patients are labeled in red.

(G) Schematic of cis-trans Xaa-Pro peptide bond isomerization catalyzed by PPIase. IS: Intermediate State.

(H and I) 2D ^1H , ^{15}N -H(C α)N ZZ exchange spectra of PRP1 peptide in the absence

(H) or presence (I) of sub-stoichiometric concentrations (1% molar ratio) of PPIL1, with appearance of 'exchange signals' (dashed circles), i.e. significant interconversion between cis-trans states.

See also Figures S5 and S6, Table S4, and Movie S1.




Figure 6. PPIL1 and PRP17 control neuronal survival independent of catalysis

(A) Pedigrees of PCHM Family 10 with homozygous PRP17 p.F502C variant segregating as a recessive trait. Filled symbols: affected; square: male; circle: female; double bar: consanguinity; diagonal line: deceased.

(B) T2-weighted brain MRI shows reduced cerebellar volume (yellow arrowhead), atrophic pons (white arrowhead) and posterior fossa fluid accumulation (yellow arrows) indicative of cerebellar atrophy in the living affected.

- (C) The structure of PRP17 resolved from the cryo-EM structure of spliceosomal C complex (PDB: 5XJC) showing mutated residue F502 within the C-terminal WD40 domain.
- (D) Protein sequence alignment of PRP17 showing mutated F502 residue highly conserved across eukaryotes. *: identical.
- (E) Western blot of overexpressed HA-tagged PRP17 shows that the p.F502C substitution destabilized the protein.
- (F) Western blot of endogenous PRP17 from dermal fibroblasts demonstrating reduced protein levels from affected (A) compared with mother (M) and unaffected control (U).
- (G) Quantification of exogenous and endogenous PRP17 protein in transfected HEK293T cells and human dermal fibroblasts, respectively. n = 3.
- (H) RT-PCR based minigene splicing assay following PRP17 repression in HEK293T cells, showing full rescue by WT or p.P95A PRP17 but only partial rescue by p.F502C PRP17.
- (I) Quantification of percent splicing inclusion (PSI) for minigene splicing reporters. PSI was calculated as percent of inclusion form transcripts among all transcripts (inclusion and exclusion forms). n = 3.
- (J) Reduced cell viability following *PRP17* repression was fully rescued by WT or p.P95A PRP17 but only partially by p.F502C PRP17. n = 4.
- (K) Coronal sections of E16.5 (top) and E18.5 (bottom) mouse brains with upregulated cleaved caspase 3 (CC3) and reduced cortical thickness in *Ppil1*^{A99T/A99T} and *Ppil1*^{R131Q/R131Q}, but not in *Ppil1*^{R55A/R55A} or *Prp17*^{P95A/P95A}. CUX1 and CTIP2 label upper and deep layer cortical neurons, respectively. Scale bar: 50 μ m.
- (L–N) Quantification of cortical CUX1⁺ and CTIP2⁺ neurons in E18.5 cortex of *Ppil1*^{R131Q/R131Q} (L), *Ppil1*^{R55A/R55A} (M), *Prp17*^{P95A/P95A} (N), and littermate controls. n = 3 mice/genotype.
- (O) Semi-quantitative RT-PCR analysis of significant RI events in *Ppil1*^{A99T/A99T} among E14.5 brains of *Ppil1*^{R131Q/R131Q} (red), *Ppil1*^{R55A/R55A} (blue), *Prp17*^{P95A/P95A} (green), and littermate controls. GAPDH as loading control.
- (P) Quantification of percent splicing inclusion (PSI) for RI events. n = 3 for each genotype. Mean \pm s.d.; p-value: ns > 0.05; * < 0.05; ** < 0.005; *** < 0.001; **** < 0.0001; one-way ANOVA test for all panels.
- See also Figure S7.

Table 1.

Clinical information of selected patients

Patient	Family 1-III:1	Family 3-III:1	Family 4-III:3	Family 5-III:1	Family 6-II:1	Family 7-II:1	Family 8-II:1	Family 9-II:1	Family 10-Y:3
Mutation gRNA (hg19)	chr6:g.368237 95C>T	chr6:g.368237 71T>C	chr6:g.368244 09T>C	chr6:g.368236 98C>T	chr6:g.[3682377 2.36823789dup; 36823765C>A]	chr6:g.[36824 397A>G]; [368 23698C>T]	chr6:g.[36823 711T>C];[368 39572G>A]	chr6:g.[36823 711T>C];[368 39572G>A]	PRP17 hg19:chr6:110 550122T>G
Mutation cDNA PP1L1 NM_016059.1, PRP17 NML_015891.2	c.295G>A	c.319A>G	c.233A>G	c.392G>A	c.[301_318dup; 325G>T]	c.[245T>C]; [392G>A]	c.[379A>G]; [280+1G>A]	c.[379A>G];[33C>T]	PRP17 c.1505T>G
Mutation Protein PP1L1 NP_057143.1, PRP17 NP_056975.1	p.Ala99Thr	p.Thr107Ala	p.Tyr78Cys	p.Arg131Gln	p.[Ala101_Asp10 6dup;Gly109Cys]	p.[Phe82Ser; Arg131Gln]	p.[Thr127Ala]; [?]	p.[Thr127Ala]; [Arg45*]	PRP17 p.Phe502Cys
Gender	Male	Male	Female	Female	Female	Male	Female	Male	Female
Ethnic origin	Egyptian	Pakistani	Mexican	Egyptian	Pakistani	Chinese	European-American	European-American	Egyptian
Parental consanguinity	+	+	+	+	-	-	-	-	+
Head circumference (HC) at birth	28cm (-6SD)	30cm (-4SD)	28cm (-4.5SD)	29cm (-4SD)	30cm (-4SD)	30cm (-2.5SD)	29cm (-4SD)	32cm (-2SD)	30cm (-3SD)
HC at last examination	36cm (-8SD) at 9 mos	39cm (-5SD) at 1 y	36cm (-8SD) at 9 mos	37cm (-6SD) at 9 mos	39cm (-5SD) at 1 y	45cm (-4SD) at 4 y	43cm (-8SD) at age 10 y	45.5cm (-6SD) at 13 y	42 cm (-5SD) at 4y
Pontocerebellar hypoplasia	+	+	+	+	+	+	+	+	+
Simplified cortical gyral patterning	+	+	+	+	+	-	+	-	-
Agenesis of corpus callosum	+	+	Partial	+	+	Partial	+	Partial	Partial
Cerebellar hypoplasia	+	+	+	+	+	+	+	+	+
Brainstem hypoplasia	+	+	+	+	+	+	+	+	+
Hydrocephalus	-	-	-	-	+	-	-	-	-
White matter abnormalities	-	-	Delayed myelination	-	-	-	-	Delayed myelination	-
Intellectual Disability	Severe	Severe	Severe	Severe	Severe	Severe	Severe	Severe	Severe

Patient	Family 1-III:1	Family 3-III:1	Family 4-III:3	Family 5-III:1	Family 6-II:1	Family 7-II:1	Family 8-II:1	Family 9-II:1	Family 10-V:3
Seizure Onset	Birth	-	Infancy	Infancy	-	Infancy	Infancy	Infancy	Infancy
Seizure Type	Focal	-	Focal	Generalized	-	Myoclonic	Infantile spasms	Infantile spasms	Myoclonic / GTC
Seizure Frequency	Intractable	-	Infrequent	Infrequent	-	Monthly	Intractable	Daily, Intractable	Intractable
Gross motor	Absent	Absent	Absent	Delayed	Absent	Delayed	Absent	Absent	Delayed
Fine motor	Absent	Absent	Absent	Absent	Absent	Delayed	Absent	Absent	Absent
Language	Absent	Absent	Absent	Absent	Absent	Delayed	Absent	Absent	Absent
Social	Absent	Absent	Absent	Absent	Absent	Delayed	Absent	Absent	Absent
Hypertonia	Mild	-	-	Mild	-	Mild	Mild	Mild	-
Hypotonia	-	Severe	Severe	Mild	Severe	-	Mild	Mild	-
Deep tendon reflexes	Brisk	Brisk	Brisk	Brisk	Brisk	-	Brisk	Brisk	Brisk
Spastic tetraplegia	+	+	+	+	++	-	+	+	+
Other	Died at 8mos; Inguinal hernia	Died at 2 mos; Persistent thrombocytopenia	Dystonia; Chronic neutropenia	Dystonia; Chronic neutropenia	Died at 2 mos	Dystonia; Chronic neutropenia	Dystonia	Dystonia	Chronic anemia and thrombocytopenia

See also Table S1 and S2.

KEY RESOURCES TABLE

REAGENT or RESOURCE
Antibodies
Mouse anti-Flag M2
Goat anti-GST
Mouse anti-SKIP
Mouse anti-beta-actin 1
Rabbit anti-CDC40/PRP17
Rabbit anti-PPIL1
Rabbit anti-CUX1
Rat anti-CTIP2
Rabbit anti-cleaved caspase3
Rabbit anti-HA
Rabbit anti-p53
Rabbit anti-PAX6
Rabbit anti-TBR2
Rabbit anti- γ -H ₂ AX
Mouse anti-SATB2
Rat anti-PH3
Mouse anti-GAD65
Mouse anti-GAD67
Bacterial and Virus Strains
BL21(DE3) E. coli cells
Rosetta™(DE3) Competent E. coli Cells
Biological Samples
Skin punch biopsy
Chemicals, Peptides, and Recombinant Proteins
Cyclosporin A
Bio-FAPEFGPENPFRT-NH ₂

REAGENT or RESOURCE
N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide
SUMO protease
Critical Commercial Assays
Click-iT™ EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit
HPLC column
Mini-PROTEAN Tris-Tricine Gel
cDNA Synthesis Kit
RNeasy Plus Mini Kit
RNAscope Multiplex Fluorescent Assays V2 kit
Deposited Data
RNA-seq data for HAP1 cells and mouse brains
Experimental Models: Cell Lines
HEK293T cells
Control HAP1 cell
<i>PPIL1</i> knockout HAP1 cell
WT and <i>PPIL1^{A99T/A99T}</i> MEF cells
Patient-derived skin fibroblast cells
Experimental Models: Organisms/Strains
Mouse, C57BL/6J, <i>Ppil1</i> frameshift (1bp del)
Mouse, C57BL/6J, <i>Ppil1^{A99T}</i> knockin
Mouse, C57BL/6J, <i>Ppil1</i> HA-tag knockin
Mouse, C57BL/6J, <i>Ppil1^{R131Q}</i> knockin
Mouse, C57BL/6J, <i>Ppil1^{R55A}</i> knockin
Mouse, C57BL/6J, <i>Ppil1^{P95A}</i> knockin
Mouse, C57BL/6J, <i>Ppil1</i> frameshift knockin
Oligonucleotides
<i>Ppil1</i> frameshift mice, gRNA: GTCTGGTCTGCGTTGGCCA
For the generation of patient mutation <i>Ppil1^{P.A99T}</i> knockin mice, gRNA: GTCTGGTCTGCGTTGGCCA; single-strand repair DNA oligo: TGCCCTTCATGCTCTTCTCTCTCCTTATGTCCCGAGGGGCTGGGATTCTCACGATGGCCAACGCAGGACCAGACACCAATGGCAGCCAGTCTTTGTGACC.
To generate <i>Ppil1</i> N-terminal HA epitope knockin mice, gRNA: GATACCTTCGCTCAGCATGG; single-strand repair DNA: CCGGGTAACTCCGCCGAAGTAGTGATTGCTAGCGGGGGGATACCTTCGCTCAGCATGTACCCATACGATGTTCCAGATTACGCGTCTCTGGCGGCGATTCCCC
For the generation of patient mutation <i>Ppil1^{P.R131Q}</i> knockin mice, gRNA: TCCCTATACCCTGGCACACT; single-strand repair DNA oligo: GGTCTGGGAGTTTGTTCACCATGCCCACCTCGATTACCATCCCTATACCTGGCACACTTGCCAAAAATAGTATGCTTGCCGTCAGCCATTGCGTGGGGGCC
To produce <i>Ppil1^{P.P95A}</i> knockin and knockout mice, gRNA: TTCCTATATCGTTGCAAGT; Single-strand repair DNA: GGATTAGAGTTGAAAATACATTGTAATTCAGGATCCTTCTTTTCCTTCTTATATCGTTGCAAGTTTGGAGCAGAAAATCCCTTTCGAACACAGCAAATGGCTGCC

REAGENT or RESOURCE
To generate of <i>Ppil1</i> ^{PR55A} knockin mice, gRNA: TGAAGTCCTTGATGATCCTG; single-strand repair DNA oligo: GTCATTGTCTGGAGCTATACTGGAAGCATGCGCCCAAGACCTGCAAGAAGTTCGCGGAGCTGGCTCGGCGGGGCTACTACAATGGCACCAAGTTTCACGCGATC
CRISPRi scramble gRNA: GCACTACCAgaGCTAACTCA
CRISPRi <i>PRP17</i> gRNA 01: CTCACTGTCCGAGTCCGATT
CRISPRi <i>PRP17</i> gRNA 02: GGACCCTGAACCCGAACCAT
CRISPRi <i>PRP17</i> gRNA 03: GCGATTAGTCAAGTGCATG
CRISPRi <i>PRP17</i> gRNA 04: GGCAGTGGACTCGGCTCCGG
Recombinant DNA
pET22b-PPIL1
pcDNA3.1-PPIL1-FLAG
pET28b-His-SUMO-PRP17(18aa)
pGEX-6P1-GST-SKIP(aa59–129)
PX330-U6–2XBsmBI-gRNA-CBh-dCas9-KRAB-T2a-Puro
pLV-hU6-sgRNA hUbc-dCas9-KRAB-T2a-Puro
pMD2.G envelope plasmid
psPAX2 packaging plasmid
pSPICEEXPRESS-Atg4d
pSPICEEXPRESS-Evi5l
pcDNA3-HA-PRP17-IRES-GFP
pINDUCER20-PPIL1
Software and Algorithms
Dynamic NMR (DNMR) module of the TopSpin 3.2 acquisition and processing software
Origin 7
Graphpad Prism 7
Adobe Illustrator
Adobe Photoshop
Inkscape
Image Lab
STAR
DESeq2
rMATS 3.2.5
Leafcutter

REAGENT or RESOURCE
WebLogo
MaxEntScan
Pymol
Other

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript